» Articles » PMID: 27346750

Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology

Overview
Specialties Neurology
Pathology
Date 2016 Jun 28
PMID 27346750
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Genome-wide association studies have established BIN1 (Bridging Integrator 1) as the most significant late-onset Alzheimer disease (AD) susceptibility locus after APOE We analyzed BIN1 protein expression using automated immunohistochemistry on the hippocampal CA1 region in 19 patients with either no, mild, or moderate-to-marked AD pathology, who had been assessed by Clinical Dementia Rating and CERAD scores. We also examined the amygdala, prefrontal, temporal, and occipital regions in a subset of these patients. In non-demented controls without AD pathology, BIN1 protein was expressed in white matter, glia, particularly oligodendrocytes, and in the neuropil in which the BIN1 signal decorated axons. With increasing severity of AD, BIN1 in the CA1 region showed: 1) sustained expression in glial cells, 2) decreased areas of neuropil expression, and 3) increased cytoplasmic neuronal expression that did not correlate with neurofibrillary tangle load. In patients with AD, both the prefrontal cortex and CA1 showed a decrease in BIN1-immunoreactive (BIN1-ir) neuropil areas and increases in numbers of BIN1-ir neurons. The numbers of CA1 BIN1-ir pyramidal neurons correlated with hippocampal CERAD neuritic plaque scores; BIN1 neuropil signal was absent in neuritic plaques. Our data provide novel insight into the relationship between BIN1 protein expression and the progression of AD-associated pathology and its diagnostic hallmarks.

Citing Articles

Human stem cell transplantation models of Alzheimer's disease.

Ifediora N, Canoll P, Hargus G Front Aging Neurosci. 2024; 16:1354164.

PMID: 38450383 PMC: 10915253. DOI: 10.3389/fnagi.2024.1354164.


Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.

Ponnusamy M, Wang S, Yuksel M, Hansen M, Blazier D, McMillan J Brain. 2022; 146(4):1561-1579.

PMID: 36059072 PMC: 10319775. DOI: 10.1093/brain/awac318.


BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia.

Sudwarts A, Ramesha S, Gao T, Ponnusamy M, Wang S, Hansen M Mol Neurodegener. 2022; 17(1):33.

PMID: 35526014 PMC: 9077874. DOI: 10.1186/s13024-022-00535-x.


Lack of association between bridging integrator 1 () rs744373 polymorphism and tau-PET load in cognitively intact older adults.

Schaeverbeke J, Luckett E, Gabel S, Reinartz M, De Meyer S, Cleynen I Alzheimers Dement (N Y). 2022; 8(1):e12227.

PMID: 35229019 PMC: 8864573. DOI: 10.1002/trc2.12227.


The Alzheimer susceptibility gene BIN1 induces isoform-dependent neurotoxicity through early endosome defects.

Lambert E, Saha O, Landeira B, Melo de Farias A, Hermant X, Carrier A Acta Neuropathol Commun. 2022; 10(1):4.

PMID: 34998435 PMC: 8742943. DOI: 10.1186/s40478-021-01285-5.


References
1.
Thomas S, Mercado J, DuHadaway J, DiGuilio K, Mullin J, Prendergast G . Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci. 2015; 61(2):423-32. DOI: 10.1007/s10620-015-3804-8. View

2.
Frost A, Unger V, De Camilli P . The BAR domain superfamily: membrane-molding macromolecules. Cell. 2009; 137(2):191-6. PMC: 4832598. DOI: 10.1016/j.cell.2009.04.010. View

3.
Wilcock D, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen K . Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003; 23(9):3745-51. PMC: 6742181. View

4.
Zhu R, Liu X, He Z . The Bridging Integrator 1 Gene Polymorphism rs744373 and the Risk of Alzheimer's Disease in Caucasian and Asian Populations: An Updated Meta-Analysis. Mol Neurobiol. 2016; 54(2):1419-1428. DOI: 10.1007/s12035-016-9760-2. View

5.
Liu L, Drouet V, Wu J, Witter M, Small S, Clelland C . Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012; 7(2):e31302. PMC: 3270029. DOI: 10.1371/journal.pone.0031302. View